Last update: Oct. 9, 2016

塩酸メベベリン

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Antispasmodic drug with direct effect on intestinal smooth muscle and little anticholinergic effects. Used for treatment of Irritable Bowel Syndrome.

At latest update no published data on excretion into breast milk were found.

Anticholinergic drugs may reduce milk production: take a minimum necessary dose and avoid long-term treatment whenever breastmilk were decreased.

Alternatives

We do not have alternatives for 塩酸メベベリン.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

塩酸メベベリン is Mebeverine Hydrochloride in Japanese.

Is written in other languages:

Group

塩酸メベベリン belongs to this group or family:

Tradenames

Main tradenames from several countries containing 塩酸メベベリン in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 466 daltons
Protein Binding 75 %
Tmax 1 - 3 hours
T1/2 1, 1 - 2,5 hours

References

  1. AEMPS. Mebeverina. Ficha técnica. 2008 Full text (in our servers)
  2. Stockis A, Guelen PJ, de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. J Pharm Biomed Anal. 2002 Abstract

Total visits

692

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM